ASCO GI 2023 Multicenter, Single-Arm, Multi-Cohort, Phase II INFINITY Trial: Tremelimumab & Durvalumab as Neoadjuvant Treatment of Patients With MSI-H Resectable GC/GEJC | VuMedi

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

10 seconds

Playback speed

ASCO GI 2023 Conference Coverage

ASCO GI 2023 Multicenter, Single-Arm, Multi-Cohort, Phase II INFINITY Trial: Tremelimumab & Durvalumab as Neoadjuvant Treatment of Patients With MSI-H Resectable GC/GEJC

By ASCO GI 2023 Conference Coverage FEATURING Filippo Pietrantonio

By ASCO GI 2023 Conference Coverage FEATURING Filippo Pietrantonio

228 views

January 31, 2023

Comments 0

Login to view comments. Click here to Login